Description & Objectives

Description & Objectives

Intended Audience

This conference is targeted towards all health-care workers in the Northwest Region who treat patients suffering from thoracic malignancies, including physicians, nurses, allied health professionals and residents.  It is especially relevant for the following specialties: primary-care, internal medicine, pulmonology, medical oncology, radiology oncology, and surgery (who work with thoracic patients).

Needs Statement

According to the American Cancer Society 2013 Cancer Facts & Figures, it was estimated that 228,190 new cases of lung cancer (the most common type of thoracic cancer) were expected in 2013, about 14% of all cancer diagnosis. Though the incidence rate has begun to decline in the past few years, lung cancer still accounts for more deaths than any other cancer in both men and women and is the second overall leading cause of death in North America after heart disease.

New improvements in radiation therapy platforms, surgical techniques, combined therapies and novelties in related fields have begun to improve survival rates; however, to continue to provide optimal, cohesive therapeutic care for thoracic cancer patients, it is necessary to rapidly disseminate knowledge of the latest advances in cancer research to oncologists and other treating physicians and allied health professionals.  Recent studies have shown that that less than a quarter of patients diagnosed with localized lung cancer received testing in the guidelines-recommended sequence, resulting in complications and unnecessary costs. Guideline-consistent care is associated with better patient outcomes and fewer invasive tests. With lung cancer screening of high risk patients becoming more common, it is essential for all treating physicians, including primary-care, to receive essential guidelines and recommendations to provide optimal patient care.

National experts will present on the following topics where knowledge and competence are needed: lung cancer screening, small peripheral cancers, lung cancer in octogenarians, stage IV adeno carcinoma, immunotherapy, social media and cancer care, T4 spine/Pancoast and modern palliation of lung cancer. Less common malignancies, arising from other intrathoracic organs such as esophagus, the pleura or the thymus, will also be reviewed.

Course Objectives

At the conclusion of this symposium, the participant will provide better patient care through an increased ability to:

  • Review the current state of lung cancer screening with CT and who should be screened; discuss how CT exams should be performed and review structured reporting and management recommendations for lung cancer screenings
  • Identify the ideal setting for a lung cancer screening program, review the essential components of a lung cancer screening program and recognize the importance of screening in a structured setting
  • Assess the risk of a lung nodule, review the role of imaging and biopsy of lung nodules and compare the treatment alternatives and outcomes for early lung cancer
  • Discuss the percentage of patients under 80 undergoing lobectomy that can be safely discharged home and review the five year actuarial survival of octogenarians after lobectomy
  • Review indications for stereotactic body radiation therapy (SBRT), discuss various SBRT treatment approaches and identify appropriate patients for SBRT
  • Describe new histologic and molecular variables for dividing patients with advanced non-small cell lung cancer (NSCLC) into subgroups with distinct optimal treatment pathways and prognosis, discuss the targeted therapies approved and being studied that have demonstrated significant improvements in clinical outcomes for patients with identified driver mutations and evaluate the utility of specific chemotherapy agents and erlotinib for distinct clinical populations that do not have an identified driver mutation
  • List the components of anti-tumor immunity, compare immunotherapy-based treatment strategies for lung cancer and review recent clinical experience with immunotherapy for lung cancer treatment
  • Recognize the shifting dynamic of the doctor/patient relationship introduced by the rapid acceleration of new medical information and availability of medical content online; identify ways in which health care professionals can use online communities and social media to counteract misinformation and increase dissemination of high quality medical information and utilize new models of clinical research that leverage online communication to facilitate trial enrollment, particularly for small, geographically diverse subgroups
  • Review the surgical principles to the complex resection of NSCLC with direct central skeletal involvement and discuss the rationale and data that supports a combined modality approach to Pancoast tumors
  • Compare the benefits and differences of the various preoperative radiation strategies in the management of surgical stage IIIA N2 NSCLC and utilize the possible management strategies of IIIA N2 NSCLC
  • Discuss the role of endoscopic therapy in early esophageal cancer, list the indications for endoscopic therapy and review the current outcomes of endoscopic therapy for early esophageal cancer
  • Review multimodality curative strategies for esophageal cancer, discuss associated toxicities and compare quality of live and cost effectiveness aspects of esophageal cancer
  • Describe the types of esophageal resection and review the outcomes including long term survival for each type of esophageal resection
  • Decide whether patients undergoing pleurectomy/decortication should undergo radiation as part of their treatment plan and discuss which modalities should be considered first line for patients undergoing EPP as part of trimodality therapy for mesothelioma
  • Review the indications for a minimally invasive thymectomy and discuss the outcomes of minimally invasive thymectomy
  • Compare the cost vs. benefits of cancer clinical research regulation; assess methods to improve cost-effectiveness of clinical research regulation; discuss why personalization of lung cancer care is essential from the perspective of quality, efficacy and cost-effectiveness of care and discuss why new clinical research structures and methods are essential in the new era of molecular medicine

Overview
Description & Objectives
Agenda
Faculty
CME Credit
Registration Fees

Online registration is now closed.

Walk-in registration will be available on-site. 

 

Date:
May 2, 2014

Time:
8 a.m.-4 p.m.

Location:
Glaser Auditorium
Swedish Medical Center/First Hill
747 Broadway
Seattle, Washington

 

Swedish Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

Contact Us

CME@swedish.org

(206) 386-2755